0001415889-20-000092.txt : 20200109 0001415889-20-000092.hdr.sgml : 20200109 20200109161014 ACCESSION NUMBER: 0001415889-20-000092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200109 DATE AS OF CHANGE: 20200109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schneiderman Daniel H CENTRAL INDEX KEY: 0001565536 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 20518277 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVE. SUITE 304 STREET 2: SUITE 207 CITY: BROOKLYN STATE: NY ZIP: 11226 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 4 1 form4-01092020_040101.xml X0306 4 2020-01-02 0001604191 AzurRx BioPharma, Inc. AZRX 0001565536 Schneiderman Daniel H 760 PARKSIDE AVE DOWNSTATE BIOTECHNOLOGY INCUBATOR STE 304 BROOKLYN NY 11226 false true false false CHIEF FINANCIAL OFFICER Options 1.03 2020-01-02 4 A 0 335006 A 2030-01-02 Common Stock 335006 335006 D Options granted in connection with the Reporting Person's appointment as Chief Financial Officer of the Issuer. The options will vest in three equal annual installments commencing on the first anniversary of the grant date, becoming fully vested on January 2, 2023. /s/ Daniel Schneiderman 2020-01-08